Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetylpyridinium Chloride and Zinc Mouthwash for Flu and Cold Symptoms
NCT06479226Phase 3Completed
- Sponsor
- Colgate-Palmolive
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Conventional Liposomes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of cetylpyridinium chloride and zinc in common cold and influenza (2 arms), sponsored by Colgate-Palmolive. Primary endpoint: Proportion of days without any evaluated upper respiratory symptoms at 90 days. Started Jun 2022; status: completed.
02
Drugs
cetylpyridinium chloridezinc
03
Conditions
common coldinfluenza
Beyond the preview
Go deeper on NCT06479226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479226.